Biosidus Expands Biological Drug Production Capacity in Argentina
Argentine biotech firm Biosidus has launched a new bioreactor facility, increasing its capacity for biological drug production and bolstering global supply capabilities.
Argentine biotechnology company Biosidus has commissioned a new production facility in Buenos Aires, significantly expanding its capacity for manufacturing biological medicines. The company announced that its new bioreactor-based unit is now operational, enhancing its ability to supply agalsidase beta globally.
The investment represents a strategic move for Biosidus, which aims to meet the growing demand for high-quality biosimilar drugs. With over four decades of experience, the company focuses on developing and producing more affordable alternatives to biological treatments, thereby improving patient access to therapies.
The launch of the new facility strengthens Biosidus' position as a key player in the regional biotechnology sector. It allows for increased production volumes and improves supply chain efficiency, crucial for competing in the global market.
Biosidus has not disclosed specific details regarding the new unit's capacity or its impact on production costs. The company continues its objective of providing high-quality, accessible biosimilar medicines to international markets.